Because of the asymmetric involvement of clinical features and plasticity in the M1 of PD patients (55), it would be ideal to conduct a prospective study in a population at high risk of developing PD (e.g., LRRK-2 mutation carriers). The gene discussed is LRRK2; the disease is Parkinson disease.